

**Supplementary information S1 (table) | EGFR docking sites and binding partners**

Tyrosine residue		Surrounding sequence	Kinase(s)	Binding partner(s)	Reference(s)
Precursor Index*	Processed Index*				
869	845	AEEKEYHAEGG	Src <sup>1,2,3</sup>	STAT1/3 <sup>&amp;</sup>	1, 2, 3
915	891	FGSKPYDGIPA	Src <sup>4</sup>	p85 <sup>4</sup> , Src <sup>4</sup>	4
944	920	CTIDVYMIMVK	Src <sup>4</sup> , Insulin Receptor Kinase <sup>#</sup>	p85 <sup>4,#</sup> , Src <sup>4</sup>	4
978	954	RDPQRYLVIQG	ND <sup>\$</sup>	PLC $\gamma$	
998	974	TDSNFYRALMD	NA <sup>\$.%</sup>	AP-2 <sup>5,%</sup>	5
1016	992	VDADEYLIPQQ	ND <sup>\$</sup>	PLC $\gamma$ <sup>6,#</sup> , PTP-1B <sup>7</sup> , RasGAP <sup>8</sup> , SHP2 <sup>8</sup>	6, 7, 8
1069	1045	SFLQRYSSDPT	ND <sup>\$</sup>	Eps15 <sup>&amp;&amp;</sup> , Cbl <sup>9</sup>	9
1092	1068	LPVPEYINQSV	EGFR <sup>10,#</sup>	Grb2 <sup>11,#</sup>	10, 11
1110	1086	VQNPVYHNQPL	EGFR <sup>12,#</sup>	Grb2 <sup>11,#</sup> , Dok-R <sup>13</sup> , Abl <sup>14</sup> , Shc <sup>#</sup>	11, 12, 13, 14
1125	1101	SRDPHYQDPHS	Src <sup>15</sup>	Abl <sup>#</sup>	15
1138	1114	VGNPEYLNTVQ	EGFR <sup>#</sup>	Shc <sup>#</sup>	
1172	1148	LDNPDYQQDFF	EGFR <sup>10,#</sup>	Shc <sup>16</sup> , Dok-R <sup>13</sup> , PTP-1B <sup>7</sup>	7, 10, 13, 16
1197	1173	AENAEYLRVAP	EGFR <sup>10,#</sup>	Shc <sup>16,#</sup> , PLC $\gamma$ <sup>6,#</sup> , SHP1 <sup>17</sup>	6, 10, 15, 17

\* Swiss-Prot entry EGFR\_HUMAN (P00533) includes a 24 amino-acid N-terminal plasma-membrane targeting motif that is subsequently cleaved. Residue indices that are based on the Swiss-Prot entry are referred to as “Precursor index”, whereas indices that are based on the sequence without the targeting motif are referred to as “Processed index”

# Predicted by Scansite (scansite.mit.edu)

\$ Not determined (ND) or not applicable (NA)

% Tyr974 does not require phosphorylation to associate with AP-2<sup>5</sup>

& Activation of this site is implicated in STAT1/3 activation, but there is no direct evidence of STAT1/3 binding to this site.

&& Ubiquitin moieties appended to activated EGFR complexes might function as docking sites for Eps15<sup>18</sup>.

-----  
-----  
Protein Abbreviations

Abl, Abelson’s protein tyrosine kinase; AP-2, Adaptor protein 2; Cbl, Casitas b-lineage lymphoma; Dok-R, Downstream of kinase related protein; Eps15, Epidermal growth factor receptor pathway substrate 15; Grb2, Growth factor receptor binding protein 2; PI3K, Phosphatidylinositol-3-kinase; p85, 85 kDa regulator subunit of PI3K; PLC $\gamma$ , Phospholipase C gamma; PTP1B, Protein tyrosine phosphatase-1B; RasGAP, Ras GTPase-activating protein; Shc, Src-homology and collagen-domain protein; SHP1, Src-homology-2 domain containing tyrosine phosphatase 1; SHP2, Src-homology-2 domain containing tyrosine phosphatase 2; Src, Sarcoma protein.

## References

1. Biscardi, J. S., Ishizawar, R. C., Silva, C. M. & Parsons, S. J. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. *Breast Cancer Res.* **2**, 203–210 (2000).
2. Maa, M. C., Leu, T. H., McCarley, D. J., Schatzman, R. C. & Parsons, S. J. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. *Proc. Natl. Acad. Sci. U S A* **92**, 6981–6985 (1995).
3. Tice, D. A., Biscardi, J. S., Nickles, A. L. & Parsons, S. J. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. *Proc. Natl. Acad. Sci. U S A* **96**, 1415–1420 (1999).
4. Stover, D. R., Becker, M., Liebetanz, J. & Lydon, N. B. Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. *J. Biol. Chem.* **270**, 15591–15597 (1995).
5. Sorkin, A., Mazzotti, M., Sorkina, T., Scotto, L. & Beguinot, L. Epidermal growth factor receptor interaction with clathrin adaptors is mediated by the Tyr974-containing internalization motif. *J. Biol. Chem.* **271**, 13377–13384 (1996).
6. Chattopadhyay, A., Vecchi, M., Ji, Q., Mernaugh, R. & Carpenter, G. The role of individual SH2 domains in mediating association of phospholipase C-gamma1 with the activated EGF receptor. *J. Biol. Chem.* **274**, 26091–26097 (1999).
7. Milarski, K. L. *et al.* Sequence specificity in recognition of the epidermal growth factor receptor by protein tyrosine phosphatase 1B. *J. Biol. Chem.* **268**, 23634–23639 (1993).
8. Agazie, Y. M. & Hayman, M. J. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. *Mol. Cell. Biol.* **23**, 7875–7886 (2003).
9. Levkowitz, G. *et al.* Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. *Mol. Cell.* **4**, 1029–1040 (1999).
10. Honegger, A. *et al.* Biological activities of EGF-receptor mutants with individually altered autophosphorylation sites. *EMBO J.* **7**, 3045–3052 (1988).
11. Okutani, T. *et al.* Grb2/Ash binds directly to tyrosines 1068 and 1086 and indirectly to tyrosine 1148 of activated human epidermal growth factor receptors in intact cells. *J. Biol. Chem.* **269**, 31310–31314 (1994).
12. Margolis, B. L. *et al.* All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor. *J. Biol. Chem.* **264**, 10667–10671 (1989).
13. Jones, N. & Dumont, D. J. Recruitment of Dok-R to the EGF receptor through its PTB domain is required for attenuation of Erk MAP kinase activation. *Curr. Biol.* **9**, 1057–1060 (1999).
14. Zhu, G. *et al.* Sequence specificity in the recognition of the epidermal growth factor receptor by the abl Src homology 2 domain. *Oncogene* **9**, 1379–1385 (1994).
15. Biscardi, J. S. *et al.* c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. *J. Biol. Chem.* **274**, 8335–8343 (1999).

16. Sakaguchi, K. *et al.* Shc phosphotyrosine-binding domain dominantly interacts with epidermal growth factor receptors and mediates Ras activation in intact cells. *Mol. Endocrinol.* **12**, 536–543 (1998).
17. Keilhack, H. *et al.* Phosphotyrosine 1173 mediates binding of the protein-tyrosine phosphatase SHP-1 to the epidermal growth factor receptor and attenuation of receptor signaling. *J. Biol. Chem.* **273**, 24839–24846 (1998).
18. de Melker, A. A., van der Horst, G. & Borst, J. Ubiquitin ligase activity of c-Cbl guides the epidermal growth factor receptor into clathrin-coated pits by two distinct modes of Eps15 recruitment. *J. Biol. Chem.* **279**, 55465–55473 (2004).